Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Ting,Zhang ^[1] ; Chengpei,Zhu ^[2] ; Nan,Zhang ^[1] ; Longhao,Zhang ^[1] ; Shanshan,Wang ^[1] ; Ziyu,Xun ^[1] ; Yiyao,Xu ^[1] ; Xiaobo,Yang ^[3] ; Xin,Lu ^[4] ; Haitao,Zhao ^[5]

作者单位： Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China. ^[1] Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China; Department of General Surgery Center, Beijing Youan Hospital, Clinical Center for Liver Cancer, Capital Medical University, Beijing, China. ^[2] Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China. Electronic address: yangxiaobo67@pumch.cn. ^[3] Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China. Electronic address: luxin@pumch.cn. ^[4] Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China. Electronic address: zhaoht@pumch.cn. ^[5]

关键词 Advanced biliary tract cancer Gemox chemotherapy Hepatic arterial infusion chemotherapy Lenvatinib PD-1 inhibitor